2seventy bio Stock (NASDAQ:TSVT)
Previous Close
$5.00
52W Range
$2.29 - $5.30
50D Avg
$4.97
200D Avg
$4.05
Market Cap
$266.14M
Avg Vol (3M)
$1.46M
Beta
1.05
Div Yield
-
TSVT Company Profile
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.